# BPC-157 (Body Protection Compound-157)

**Last Updated:** December 4, 2025
**Evidence Level:** OCEBM Level 5 (Animal studies + mechanism-based reasoning)
**Risk Profile:** LOW-MODERATE (Theoretical oncogenesis concern)

---

## What Is This?

BPC-157 is a peptide derived from a protective protein found in human stomach juice. It has shown remarkable healing properties in animal studies — accelerating repair of tendons, ligaments, muscles, gut lining, and even nerves. Despite widespread use in the wellness community, almost all evidence comes from animal research; human clinical trials are just beginning.

---

## Categories

`Tissue Repair` · `Gut Health` · `Bone & Joint`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — a rating system for medical evidence strength |
| NO system / eNOS | Nitric oxide system — blood vessels use this to relax and improve blood flow; eNOS is the enzyme that makes it |
| VEGFR2-Akt-eNOS pathway | A signalling chain that promotes blood vessel growth and tissue repair |
| Angiogenesis | The growth of new blood vessels (beneficial for healing, but tumours also use this to grow) |
| VEGF / EGF | Growth factors that stimulate new blood vessel and tissue formation |
| NF-κB | A protein complex controlling inflammation; blocking it reduces inflammatory responses |
| Cytoprotective | Protects cells from damage |
| Oncogenesis | The process by which normal cells become cancer cells |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Weight | 1419.53 g/mol |
| Half-life | **15-30 minutes** (plasma) |
| Bioavailability | IM: 14-19% (rats), 45-51% (dogs); Oral: variable |
| Stability | Stable in gastric acid (unique among peptides) |
| FDA Status | Category 2 (compounding prohibited) |
| WADA Status | Prohibited (S0, non-approved substance) |

---

## Clinical Evidence

### The Human Data Gap

The central frustration with BPC-157 is the vast disconnect between its preclinical promise and clinical validation. A 2024 systematic review screened 544 articles spanning three decades (1993–2024) and found only 36 studies worth including — of which 35 were preclinical. The conclusion was unambiguous: strong animal data, insufficient human evidence.

### What We Know from Humans

The first formal safety study in humans appeared only in 2025. Lee and Burgess administered intravenous BPC-157 at doses up to 20mg in two healthy adults. No adverse events emerged, and cardiac, hepatic, renal, and thyroid biomarkers remained unchanged. This is encouraging for safety but tells us nothing about efficacy.

A small pilot study (n=12) examined single intra-articular injections for knee pain. Seven of twelve patients reported relief lasting beyond six months — suggestive, but far from definitive without a control group.

### The Animal Evidence

In rodent models, BPC-157's effects border on implausible in their breadth. Transected Achilles tendons heal faster with improved tensile strength. NSAID-induced gastric ulcers are nearly completely prevented. Crushed muscles recover more rapidly. Severed peripheral nerves regenerate. Inflamed bowels show mucosal healing. The consistency across injury types suggests BPC-157 operates through fundamental repair pathways rather than tissue-specific mechanisms.

### Interpreting the Evidence

Nearly all positive data originates from a single research group led by Predrag Sikiric in Zagreb. While their work is meticulous, the absence of independent replication is a significant limitation. Publication bias likely inflates the effect size — failed studies rarely see print. Until Western clinical trials produce data, BPC-157 remains a compelling hypothesis rather than a proven therapy.

---

## Mechanism of Action

BPC-157 appears to orchestrate healing through several interconnected systems. Its primary action involves the nitric oxide system, where it activates endothelial nitric oxide synthase (eNOS), causing blood vessels to dilate and improving blood flow to injured tissues. This vasodilation alone would accelerate healing by delivering more oxygen and nutrients to damaged areas.

The peptide also triggers the VEGFR2-Akt-eNOS signalling cascade, which promotes angiogenesis — the growth of new blood vessels into injured tissue. While this is precisely what healing requires, it is also the pathway tumours exploit for their own blood supply, which explains the theoretical oncogenesis concern.

Beyond vascular effects, BPC-157 sensitises receptors for growth factors like VEGF and EGF, amplifying the body's native repair signals. It simultaneously dampens inflammation by modulating cytokine release and interfering with the NF-κB pathway, creating conditions where repair can proceed without excessive inflammatory damage.

The peptide's origin in gastric juice may explain its remarkable stability in stomach acid — a property almost unique among peptides — and its particular efficacy for gastrointestinal healing.

---

## Use Cases by Goal

### Acute Injury Healing (Tendon, Ligament, Muscle)

BPC-157's most compelling use case is accelerating recovery from soft tissue injuries. The rationale is straightforward: by enhancing blood flow, stimulating growth factors, and promoting new vessel formation, the peptide creates optimal conditions for tissue repair.

**Protocol:** 250-500mcg SC near injury site, 2x daily
**Duration:** 2-4 weeks (most injuries) or until healed
**Timing:** Morning + evening, spaced 8-12 hours apart

### Gut Healing / GI Issues

Given BPC-157's origin in gastric secretions, its application to gastrointestinal conditions carries a certain logic. Animal models show exceptional mucosal healing in IBD, protection from NSAID-induced ulceration, and general cytoprotective effects throughout the GI tract.

**Use For:** IBD flares, leaky gut, NSAID damage, ulcers, IBS support

**Protocol:** 250-500mcg oral (stable in stomach acid)
**Duration:** 4-8 weeks
**Timing:** Empty stomach, 30 min before meals

### Post-Surgical Recovery

The same mechanisms that accelerate injury healing apply to surgical wounds. Anecdotal reports from surgeons noting unusually rapid healing in patients using BPC-157 are intriguing but uncontrolled.

**Protocol:** 250mcg 2x daily SC, starting 1-2 days post-op (with surgeon approval)
**Duration:** 2-4 weeks post-surgery

---

## Anecdotal / Unvalidated Protocols (No Controlled Human Data)

### Dopaminergic System Reset

Some users report that BPC-157 modulates dopamine systems, helping restore sensitivity to stimulants after prolonged use or aiding addiction recovery. Animal studies support dopamine system interactions, but no controlled human data exists.

**Protocol:** 250-500mcg daily
**Duration:** 2-4 weeks
**Caution:** Effects on dopamine may persist 1+ week post-use

### Prevention / Longevity (Systemic Protection)

The peptide's name — Body Protection Compound — reflects its broad cytoprotective effects in animal models. Some users employ low-dose cycles as general tissue maintenance.

**Protocol:** 250mcg daily SC
**Duration:** 4-8 week cycles, 2-4x per year
**Timing:** Evening (some report it helps sleep)

### Injury Prevention (Athletes)

Prophylactic use during intense training blocks aims to support tissue integrity before damage accumulates.

**Protocol:** 250mcg daily during heavy training blocks
**Duration:** 4-6 weeks
**Timing:** Evening or post-training

**Note:** CNS effects (dopamine, mood) are anecdotal only; no controlled human data exists.

---

## Anecdotal Reports (User Experiences)

**Note:** These are unverified reports from online forums and should not be considered medical evidence.

| Use Case | User Reports |
|----------|--------------|
| Injury healing | *"Rotator cuff tear healed in 6 weeks instead of 12"*, *"Tennis elbow resolved after 3 weeks"*, *"Achilles tendinopathy finally improving"* |
| Gut healing | *"IBS symptoms reduced by 70%"*, *"Could tolerate NSAIDs again for my joints"*, *"Gut inflammation calmed significantly"* |
| Post-surgery | *"Surgeon commented on unusually fast healing"*, *"Back to activity faster than predicted"* |
| Dopamine reset | *"Caffeine sensitivity returned after years of tolerance"*, *"Helped reduce stimulant dependence"*, *"Motivation baseline improved"* |
| General wellness | *"General resilience improved"*, *"Recover from everything faster"* |
| Athletic use | *"Survived intense training block without usual tweaks"*, *"Joints feel more resilient"* |

---

## Timing and Administration

### Injection Protocols

| Application | Route | Location |
|-------------|-------|----------|
| Localized injury | SC | Near injury site (within 2-3 inches) |
| Systemic/GI | SC | Abdominal fat (any site) |
| GI-specific | Oral | Empty stomach |

### Timing Strategies

| Goal | Best Time |
|------|-----------|
| Injury healing | 2x daily, evenly spaced |
| GI healing | 30 min before meals |
| General wellness | Once daily, evening |
| Post-workout | Within 30 min of training |

### Duration Recommendations

| Condition | Duration |
|-----------|----------|
| Acute soft tissue injury | 2-4 weeks |
| Chronic tendinopathy | 4-8 weeks |
| GI healing | 4-8 weeks |
| Post-surgical | 2-4 weeks |
| Dopamine reset | 2-4 weeks |
| General wellness cycle | 4-6 weeks |

---

## User Experience Timeline

| Timeframe | Reported Effects |
|-----------|------------------|
| Days 1-3 | Some report immediate reduction in pain/inflammation |
| Week 1 | Noticeable improvement in acute injuries |
| Week 2-3 | Significant healing progress |
| Week 4+ | Resolution or major improvement |

**Individual variation is significant.** Some respond dramatically; others report minimal effects.

---

## Stacking Options

### With TB-500 (Comprehensive Healing)

The combination of BPC-157 and TB-500 represents a "belt and suspenders" approach to serious injuries. While BPC-157 works primarily through the nitric oxide system and local growth factor signalling, TB-500 operates via actin regulation and systemic stem cell mobilisation. These complementary mechanisms may produce synergistic healing effects, though no controlled studies have compared the combination to either peptide alone.

**Protocol:** BPC-157 250mcg 2x daily + TB-500 2mg 2x weekly

### With GHK-Cu (Collagen Focus)

For injuries where collagen quality matters — tendons, ligaments, skin — combining BPC-157's tissue repair signalling with GHK-Cu's collagen synthesis stimulation addresses both the repair process and the building material.

### With Ipamorelin (Comprehensive Recovery)

Adding growth hormone stimulation via Ipamorelin to BPC-157's local repair effects creates a systemic recovery environment. This combination is often used during injury rehabilitation when general anabolic support is desired alongside targeted tissue healing.

---

## Dosing Summary

| Protocol | Dose | Frequency | Route | Duration |
|----------|------|-----------|-------|----------|
| Standard injury | 250-500mcg | 2x daily | SC near injury | 2-4 weeks |
| GI healing | 250-500mcg | 1-2x daily | Oral | 4-8 weeks |
| Maintenance | 250mcg | 1x daily | SC abdomen | 4-6 weeks |
| High dose | 500-1000mcg | 1-2x daily | SC | 2-4 weeks |

---

## Side Effects

| Effect | Frequency | Notes |
|--------|-----------|-------|
| Injection site irritation | Common | Rotate sites |
| Nausea | Uncommon | Usually transient |
| Dizziness | Uncommon | |
| Headache | Uncommon | |
| Fatigue | Rare | Some find it calming |
| Altered caffeine response | Reported | Dopaminergic effects |

---

## Oncogenesis Risk Assessment

### The Theoretical Concern

BPC-157's healing power comes from the same biological machinery that tumours exploit. The peptide activates VEGF and promotes angiogenesis — the growth of new blood vessels. This is precisely what injured tissue needs to heal, but it is also how cancers establish their blood supply and metastasise. Any compound that promotes blood vessel growth carries theoretical oncogenic risk.

### Evidence Against Cancer Promotion

The theoretical concern, however, is not supported by available evidence. In melanoma studies, BPC-157 actually *inhibited* tumour cell growth rather than promoting it. In cancer cachexia models, the peptide prolonged survival and counteracted muscle wasting without accelerating tumour progression. These findings suggest the relationship between BPC-157 and cancer is more nuanced than simple pro-angiogenic risk would predict.

### Current Assessment

No human data on cancer risk exists. The animal data is mixed but includes some anti-tumour effects. Until long-term human studies clarify the picture, prudence dictates caution in high-risk individuals.

**Avoid or use with caution in:**
- Active malignancy
- Strong personal or family history of cancer
- Angiogenesis-dependent cancers (certain solid tumours)

### Risk Mitigation Rules

1. **Avoid** in anyone with current cancer or strong personal history
2. **Avoid chronic continuous use:** Limit to 2-4 week blocks with long off-periods
3. **Do not combine** with other strong pro-angiogenic interventions

### Monitoring (Long-Term Use)

| Test | Baseline | Ongoing | Rationale |
|------|----------|---------|-----------|
| PSA (men >40) | Yes | Every 6 months | Prostate surveillance |
| CEA | Yes | Every 6 months | Colorectal marker |
| CA-125 (women) | Yes | Every 6 months | Ovarian surveillance |
| CA 19-9 (if GI history) | Yes | Every 6 months | Pancreatic/GI marker |
| Mole/skin changes | Yes | Monthly self-exam | Melanoma screening |

### Tumour Marker Cessation Rule

**Any elevation in PSA, CEA, or CA-125: Immediate cessation of ALL growth factors** (GH peptides, BPC-157, TB-500, GHK-Cu, Dihexa)

---

## Contraindications

- Active malignancy
- Pregnancy/breastfeeding
- Active bleeding (pro-angiogenic concern)

---

## Limitations

1. **OCEBM Level 5** — Nearly all evidence from animal studies
2. **Single research group bias** — Most studies from Sikiric et al.
3. **Publication bias** — Negative studies unlikely published
4. **Long-term safety unknown**
5. **Drug interactions unstudied**

---

## References

1. Pharmacokinetics of BPC-157. Front Pharmacol. 2022. PMC9794587
2. Vasireddi N, et al. BPC-157 in Orthopaedic Sports Medicine: Systematic Review. 2025. PMC12313605
3. Lee & Burgess. Safety of IV BPC-157 in Humans. 2025. PMID: 40131143
4. BPC 157 inhibits melanoma cell growth. Melanoma Res. 2004.
5. Sikiric P, et al. BPC 157 Controlling Angiogenesis. Pharmaceuticals. 2025. PMC12195719
6. User experience from r/peptides, clinical reports, longevity forums.
